Seoul Economic Daily EnglishCodex · 实盘不做把握 5/10不做原因:证据不足
北京时间·🕒 发布 12:35:56(首尔 13:35)·⟳ 抓取 12:46:07 +10m11s·⚡ 决策 08-24 12:56:40 +10m33s·64.1 天前
韩美药品将肌肉保留型肥胖药HM17321授权给Genentech，最高金额23.05亿美元
事件本身对韩美药品方向明确偏正面，但缺少本轮强制工具的实时成交价、去重、案例库和event_study校验，按契约不能给ENTER。
📄 原文Seoul Economic Daily English↗ 原文
Hanmi Licenses Muscle-Sparing Obesity Drug to Genentech in $2 Billion Deal
Hanmi Pharmaceutical will license a next-generation obesity drug candidate designed to reduce body weight while preserv…
不做 韩美药品（128940.KS）
事件方向明确正面且量级不小，但本轮无法取得强制实时行情、内部去重、案例库和event_study；按契约不能在缺少stock_quote真实价的情况下给ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
韩美药品把1期肥胖/代谢病候选药HM17321授权给Genentech，1.90亿美元首付款约2629亿韩元，相当于其2025年收入约17%和近期市值约5%；这类全球药企背书通常是直接利好。但该股在消息前一个月已从约31万韩元升至41.55万韩元，且无法确认事件后实时价格、是否已高开重定价和同类授权先例超额收益，因此不下交易单。
消息传播链
- Chosunbiz报道韩美药品将HM17321授权给Genentech，最高金额超过3万亿韩元。
- Yakup按公司披露口径列明1.90亿美元首付款、21.15亿美元里程碑和韩国除外全球授权范围。
- 投研Telegram转发DART披露摘要，并给出韩美药品市值约5.76万亿韩元。
- 英文稿完整披露HM17321机制、FDA IND、1期状态和Genentech后续开发安排。
关键理由
- 1.90亿美元不可退首付款约2629亿韩元，对韩美药品2025年收入1.55万亿韩元约17%，对约5.06万亿韩元市值约5.2%，短线量级足够被市场关注。
- Genentech承担韩国以外全球开发、生产和商业化，降低韩美药品后续开发负担并验证HM17321差异化机制。
- HM17321仍为1期早期资产，最高23.05亿美元主要是条件里程碑，实际兑现取决于临床、审批和商业化。
主要风险
- 近一个月韩美药品股价已大幅反弹，存在肥胖药和前次Lilly授权预期已部分price-in的风险。
- HSR等行政程序满足后协议才生效，且临床/审批/商业化未达标时里程碑不会兑现。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-16 · 影响 weakens
IBK报告称北京韩美受中国集采降价压力影响，子公司业绩偏弱，是集团基本面反向因素。
检索:Hanmi Pharmaceutical risks China procurement Beijing Hanmi 2026 Q2 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-24 · 影响 weakens
协议需HSR等行政程序满足后生效，且未实现临床、审批、商业化条件时里程碑不会兑现。
检索:Hanmi HM17321 Genentech HSR clinical milestone termination 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例支持事件方向为正，但因缺少event_study和实时行情，最终由ENTER降为AVOID。
方向:高相似的同公司Lilly授权指向正面，但同主题反例显示授权消息若已预期或条款质量低会高开低走。
涨幅量级:唯一高相似样本显示可出现约10%以上的即时反应，但样本数不足，不能据此直接设定tp/sl。
形态:韩国肥胖药授权主题存在强beta和见光死并存特征，追高风险需要用实时价和成交确认控制。
历史先例(按相似度)
- 相似度 8/10 128940 2026-06-01 韩美药品与Eli Lilly签署12.6亿美元授权协议后，盘前报价一度上涨约13%-17%。 原文 ↗
事件后 +1日 +9.8% · +2日 +3.3% · +3日 +0.1% · +4日 +0.6% · +5日 -15.9%
⚠相位不对齐(pre!=target_unknown) — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同为全球药企授权、同为大额首付款/里程碑，但适应症和研发阶段不同。
经验:同一公司大药企授权可在盘前/早盘触发两位数级别重定价。 - 相似度 6/10 000250 2026-02-27 Sam Chun Dang Pharm欧洲口服Wegovy相关协议后两日上涨，其中前一日涨停、次日盘中再涨约9%。 原文 ↗
事件后 +1日 +9.0% · +2日 -0.4% · +3日 -14.8% · +4日 +5.2% · +5日 +0.9%
⚠锚前1-2日已异动29.9%>锚定日9.0%·盘中首发但只有日线，混入首发前走势 — 该行涨幅别用来定止盈止损
相似度依据:同属韩国肥胖药授权/商业化协议，但标的是仿制口服司美格鲁肽，商业模式和金额质量不同。
经验:肥胖药授权主题可短线连续大涨，但后续若条款低于预期也可能快速回撤。 - 相似度 5/10 000250 2026-03-31 Sam Chun Dang Pharm美国口服司美格鲁肽协议披露后，因催化兑现低于市场预期，早盘下跌约21%。 原文 ↗
事件后 +1日 -30.0% · +2日 -37.8% · +3日 -48.6% · +4日 -45.3% · +5日 -47.8%
⚠盘中首发但只有日线，混入首发前走势 — 该行涨幅别用来定止盈止损
相似度依据:同为韩国肥胖药授权消息，但该案例为市场预期落空和sell-the-news，作为反例。
经验:若授权条款或对手方披露不及此前预期，肥胖药授权消息会出现见光死。
原文全文
展开原文 · 2,418 字
Hanmi Pharmaceutical will license a next-generation obesity drug candidate designed to reduce body weight while preserving muscle to Genentech, a subsidiary of Swiss drugmaker Roche, in a deal worth up to 3.2 trillion won ($2.3 billion).
Hanmi said in a regulatory filing on the 24th that it had signed an exclusive licensing agreement with Genentech for HM17321, a candidate to treat metabolic diseases including obesity, type 2 diabetes and cardiovascular disease. Under the deal, Genentech secured exclusive rights to develop, manufacture and commercialize HM17321 worldwide, excluding Korea.
Hanmi will receive a non-refundable upfront payment of $190 million (about 262.9 billion won). The total deal size, including milestone payments tied to clinical development, regulatory approval and commercialization, reaches up to $2.31 billion (about 3.19 trillion won). Hanmi will also separately collect tiered royalties linked to sales after the product's launch.
HM17321 is a urocortin-2 (UCN2) analog that works through a different mechanism from the existing incretin class based on glucagon-like peptide (GLP)-1, which regulates appetite and blood sugar. It is being developed as a potential first-in-class drug that addresses a limitation of existing treatments, which reduce lean body mass, including muscle, during weight loss.
In preclinical studies, HM17321 showed effects on weight loss and body composition both when administered alone and in combination with GLP-1 class treatments. As a peptide-based treatment, it holds potential for broader development, such as a fixed-dose combination combining it with a GLP-1 treatment in a single product or as a combination therapy.
Hanmi received approval for its investigational new drug application from the U.S. Food and Drug Administration (FDA) last November and is currently conducting a Phase 1 trial in healthy adults and obese patients. The trial evaluates safety, tolerability, pharmacokinetics and pharmacodynamics. After Hanmi completes the Phase 1 trial, Genentech will lead subsequent development from Phase 2.
Choi In-young, senior vice president at Hanmi Pharmaceutical, stressed that "obesity treatment is evolving beyond simple weight loss toward improving body composition and restoring metabolic health." Choi added that the deal is "recognition in the global market of HM17321's differentiated mechanism of action and development potential."
Hanmi said in a regulatory filing on the 24th that it had signed an exclusive licensing agreement with Genentech for HM17321, a candidate to treat metabolic diseases including obesity, type 2 diabetes and cardiovascular disease. Under the deal, Genentech secured exclusive rights to develop, manufacture and commercialize HM17321 worldwide, excluding Korea.
Hanmi will receive a non-refundable upfront payment of $190 million (about 262.9 billion won). The total deal size, including milestone payments tied to clinical development, regulatory approval and commercialization, reaches up to $2.31 billion (about 3.19 trillion won). Hanmi will also separately collect tiered royalties linked to sales after the product's launch.
HM17321 is a urocortin-2 (UCN2) analog that works through a different mechanism from the existing incretin class based on glucagon-like peptide (GLP)-1, which regulates appetite and blood sugar. It is being developed as a potential first-in-class drug that addresses a limitation of existing treatments, which reduce lean body mass, including muscle, during weight loss.
In preclinical studies, HM17321 showed effects on weight loss and body composition both when administered alone and in combination with GLP-1 class treatments. As a peptide-based treatment, it holds potential for broader development, such as a fixed-dose combination combining it with a GLP-1 treatment in a single product or as a combination therapy.
Hanmi received approval for its investigational new drug application from the U.S. Food and Drug Administration (FDA) last November and is currently conducting a Phase 1 trial in healthy adults and obese patients. The trial evaluates safety, tolerability, pharmacokinetics and pharmacodynamics. After Hanmi completes the Phase 1 trial, Genentech will lead subsequent development from Phase 2.
Choi In-young, senior vice president at Hanmi Pharmaceutical, stressed that "obesity treatment is evolving beyond simple weight loss toward improving body composition and restoring metabolic health." Choi added that the deal is "recognition in the global market of HM17321's differentiated mechanism of action and development potential."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。